The Roskamp Institute is pleased to announce that its third-annual signature event, Grey Matters—A Symposium on Alzheimer’s Disease Research, is half sold after registration opening only a few weeks ago.
| SARASOTA, Fla., April 9, 2019 /PRNewswire/ -- The Roskamp Institute is pleased to announce that its third-annual signature event, Grey Matters—A Symposium on Alzheimer’s Disease Research, is half sold after registration opening only a few weeks ago. “We are thrilled with the outpouring of support for GM3 (Grey Matters) event. The level of interest speaks to the fact that diseases of the brain, such as Alzheimer’s and others, impact people and their families in so many ways,” said Roskamp Institute CEO Fiona Crawford, Ph.D. Current research from the Alzheimer’s Association found that one in nine people age 65 and older have Alzheimer’s dementia. By 2050, it is estimated that more than 16 million Americans will have Alzheimer’s disease, with 135 million people affected worldwide—figures that do not take into account patients’ loved ones and caretakers. The emotional and financial costs of the disease are staggering. Speakers at this interactive luncheon will provide updates on potential treatments, lifestyle choices that help prevent degeneration, and information and help for caregivers. This year’s event will feature New York Times bestselling author, Kimberley Williams-Paisley, and speakers from The Roskamp Institute, who will share updates and answer questions from the audience. Funds raised from GM3 will directly support the medical research currently conducted at The Roskamp Institute. After establishing research facilities locally in 2003, The Roskamp Institute has made important discoveries with profound clinical implications for millions of Americans suffering from Alzheimer’s disease and other debilitating neurological disorders. The Institute is a leader in the international research community with its programs and projects supported by the National Institutes of Health, the Department of Defense, the Veterans Administration, the European Commission Seventh Framework Programme, and several other national and international peer-reviewed agencies. In addition to Alzheimer’s disease treatments, the Institute focuses on the development of new drugs and therapies to treat neurological disorders such as Traumatic Brain Injury, Gulf War Illness, Multiple Sclerosis, and other neuroinflammatory disorders. For information on remaining sponsorships, please call Megan Micale at (941) 552-9832 or email mmicale@roskampfoundation.org. RECENT HIGHLIGHTS: YOUTUBE VIDEO LINK: INFORMATION ON OTHER UPCOMING ROSKAMP INSTITUTE EVENTS: ABOUT THE ROSKAMP INSTITUTE
SOURCE Roskamp Institute |
View original content:
